nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP2C9—Capecitabine—stomach cancer	0.0176	0.237	CbGbCtD
Bortezomib—CYP2C8—Fluorouracil—stomach cancer	0.015	0.201	CbGbCtD
Bortezomib—CYP1A2—Fluorouracil—stomach cancer	0.0116	0.156	CbGbCtD
Bortezomib—CYP2C9—Fluorouracil—stomach cancer	0.0105	0.14	CbGbCtD
Bortezomib—CYP3A4—Irinotecan—stomach cancer	0.00634	0.085	CbGbCtD
Bortezomib—CYP2D6—Doxorubicin—stomach cancer	0.00545	0.073	CbGbCtD
Bortezomib—CTSG—hematopoietic system—stomach cancer	0.00543	0.0319	CbGeAlD
Bortezomib—PSMA1—hematopoietic system—stomach cancer	0.00521	0.0307	CbGeAlD
Bortezomib—PSMA1—epithelium—stomach cancer	0.00476	0.028	CbGeAlD
Bortezomib—CYP3A4—Docetaxel—stomach cancer	0.00465	0.0623	CbGbCtD
Bortezomib—PSMD2—hematopoietic system—stomach cancer	0.00387	0.0228	CbGeAlD
Bortezomib—PSMD1—smooth muscle tissue—stomach cancer	0.00385	0.0227	CbGeAlD
Bortezomib—CTSG—lymphoid tissue—stomach cancer	0.00382	0.0225	CbGeAlD
Bortezomib—PSMA1—lymphoid tissue—stomach cancer	0.00367	0.0216	CbGeAlD
Bortezomib—PSMA1—digestive system—stomach cancer	0.00362	0.0213	CbGeAlD
Bortezomib—PSMD1—pancreas—stomach cancer	0.00356	0.021	CbGeAlD
Bortezomib—CTSG—bone marrow—stomach cancer	0.00348	0.0205	CbGeAlD
Bortezomib—CYP3A4—Doxorubicin—stomach cancer	0.00346	0.0464	CbGbCtD
Bortezomib—PSMD2—smooth muscle tissue—stomach cancer	0.00341	0.0201	CbGeAlD
Bortezomib—PSMA1—bone marrow—stomach cancer	0.00334	0.0197	CbGeAlD
Bortezomib—PSMD2—pancreas—stomach cancer	0.00315	0.0186	CbGeAlD
Bortezomib—PSMB8—pancreas—stomach cancer	0.00313	0.0185	CbGeAlD
Bortezomib—CTSG—endocrine gland—stomach cancer	0.00312	0.0184	CbGeAlD
Bortezomib—PSMB5—smooth muscle tissue—stomach cancer	0.003	0.0176	CbGeAlD
Bortezomib—PSMA1—endocrine gland—stomach cancer	0.00299	0.0176	CbGeAlD
Bortezomib—PSMB1—hematopoietic system—stomach cancer	0.00297	0.0175	CbGeAlD
Bortezomib—PSMB2—hematopoietic system—stomach cancer	0.0029	0.0171	CbGeAlD
Bortezomib—PSMD1—bone marrow—stomach cancer	0.0028	0.0165	CbGeAlD
Bortezomib—PSMB5—pancreas—stomach cancer	0.00277	0.0163	CbGeAlD
Bortezomib—PSMD2—lymphoid tissue—stomach cancer	0.00273	0.0161	CbGeAlD
Bortezomib—PSMA1—liver—stomach cancer	0.0027	0.0159	CbGeAlD
Bortezomib—PSMD2—digestive system—stomach cancer	0.00269	0.0159	CbGeAlD
Bortezomib—PSMB1—smooth muscle tissue—stomach cancer	0.00262	0.0154	CbGeAlD
Bortezomib—PSMB2—smooth muscle tissue—stomach cancer	0.00255	0.015	CbGeAlD
Bortezomib—PSMD2—bone marrow—stomach cancer	0.00248	0.0146	CbGeAlD
Bortezomib—PSMB8—bone marrow—stomach cancer	0.00247	0.0145	CbGeAlD
Bortezomib—PSMB1—pancreas—stomach cancer	0.00242	0.0143	CbGeAlD
Bortezomib—PSMB2—pancreas—stomach cancer	0.00236	0.0139	CbGeAlD
Bortezomib—PSMD1—liver—stomach cancer	0.00227	0.0133	CbGeAlD
Bortezomib—PSMD2—endocrine gland—stomach cancer	0.00223	0.0131	CbGeAlD
Bortezomib—PSMB5—bone marrow—stomach cancer	0.00218	0.0128	CbGeAlD
Bortezomib—CTSG—lymph node—stomach cancer	0.00216	0.0127	CbGeAlD
Bortezomib—PSMB1—lymphoid tissue—stomach cancer	0.00209	0.0123	CbGeAlD
Bortezomib—PSMA1—lymph node—stomach cancer	0.00207	0.0122	CbGeAlD
Bortezomib—PSMB1—digestive system—stomach cancer	0.00207	0.0122	CbGeAlD
Bortezomib—PSMB2—lymphoid tissue—stomach cancer	0.00204	0.012	CbGeAlD
Bortezomib—PSMB2—digestive system—stomach cancer	0.00202	0.0119	CbGeAlD
Bortezomib—PSMD2—liver—stomach cancer	0.00201	0.0118	CbGeAlD
Bortezomib—Lacosamide—CA1—stomach cancer	0.002	0.415	CrCbGaD
Bortezomib—PSMB8—liver—stomach cancer	0.00199	0.0117	CbGeAlD
Bortezomib—PSMB1—bone marrow—stomach cancer	0.00191	0.0112	CbGeAlD
Bortezomib—PSMB2—bone marrow—stomach cancer	0.00186	0.0109	CbGeAlD
Bortezomib—PSMB5—liver—stomach cancer	0.00176	0.0104	CbGeAlD
Bortezomib—SLC31A1—digestive system—stomach cancer	0.00175	0.0103	CbGeAlD
Bortezomib—PSMD1—lymph node—stomach cancer	0.00174	0.0102	CbGeAlD
Bortezomib—PSMB1—endocrine gland—stomach cancer	0.00171	0.0101	CbGeAlD
Bortezomib—PSMB2—endocrine gland—stomach cancer	0.00167	0.00981	CbGeAlD
Bortezomib—SLC31A1—bone marrow—stomach cancer	0.00161	0.00948	CbGeAlD
Bortezomib—PSMB1—liver—stomach cancer	0.00154	0.00907	CbGeAlD
Bortezomib—PSMD2—lymph node—stomach cancer	0.00154	0.00906	CbGeAlD
Bortezomib—PSMB8—lymph node—stomach cancer	0.00153	0.00901	CbGeAlD
Bortezomib—Lacosamide—CA2—stomach cancer	0.00152	0.314	CrCbGaD
Bortezomib—PSMB2—liver—stomach cancer	0.0015	0.00885	CbGeAlD
Bortezomib—SLC31A1—endocrine gland—stomach cancer	0.00144	0.0085	CbGeAlD
Bortezomib—PTGS1—blood vessel—stomach cancer	0.00141	0.00829	CbGeAlD
Bortezomib—PSMB5—lymph node—stomach cancer	0.00135	0.00795	CbGeAlD
Bortezomib—SLC31A1—liver—stomach cancer	0.0013	0.00766	CbGeAlD
Bortezomib—PSMB1—lymph node—stomach cancer	0.00118	0.00695	CbGeAlD
Bortezomib—PSMB2—lymph node—stomach cancer	0.00115	0.00678	CbGeAlD
Bortezomib—CYP2C19—hematopoietic system—stomach cancer	0.00106	0.00623	CbGeAlD
Bortezomib—SLC31A1—lymph node—stomach cancer	0.000998	0.00587	CbGeAlD
Bortezomib—Nateglinide—PPARG—stomach cancer	0.000951	0.197	CrCbGaD
Bortezomib—CYP2C8—hematopoietic system—stomach cancer	0.000924	0.00544	CbGeAlD
Bortezomib—CYP1A2—hematopoietic system—stomach cancer	0.000865	0.00509	CbGeAlD
Bortezomib—CYP1A1—hematopoietic system—stomach cancer	0.000853	0.00502	CbGeAlD
Bortezomib—CYP2C9—hematopoietic system—stomach cancer	0.000821	0.00483	CbGeAlD
Bortezomib—CYP1A1—epithelium—stomach cancer	0.00078	0.00459	CbGeAlD
Bortezomib—PTGS1—hematopoietic system—stomach cancer	0.000749	0.00441	CbGeAlD
Bortezomib—CYP2C19—digestive system—stomach cancer	0.000736	0.00434	CbGeAlD
Bortezomib—PTGS1—epithelium—stomach cancer	0.000685	0.00403	CbGeAlD
Bortezomib—PTGS1—smooth muscle tissue—stomach cancer	0.00066	0.00389	CbGeAlD
Bortezomib—CYP3A4—hematopoietic system—stomach cancer	0.000626	0.00369	CbGeAlD
Bortezomib—CYP2D6—hematopoietic system—stomach cancer	0.000616	0.00363	CbGeAlD
Bortezomib—CYP2C19—endocrine gland—stomach cancer	0.000608	0.00358	CbGeAlD
Bortezomib—CYP1A2—digestive system—stomach cancer	0.000601	0.00354	CbGeAlD
Bortezomib—CYP1A1—digestive system—stomach cancer	0.000593	0.00349	CbGeAlD
Bortezomib—CYP2C9—digestive system—stomach cancer	0.000571	0.00336	CbGeAlD
Bortezomib—CYP2C19—liver—stomach cancer	0.000549	0.00323	CbGeAlD
Bortezomib—CYP2C8—endocrine gland—stomach cancer	0.000531	0.00313	CbGeAlD
Bortezomib—PTGS1—digestive system—stomach cancer	0.000521	0.00307	CbGeAlD
Bortezomib—CYP1A2—endocrine gland—stomach cancer	0.000497	0.00293	CbGeAlD
Bortezomib—CYP1A1—endocrine gland—stomach cancer	0.00049	0.00289	CbGeAlD
Bortezomib—CYP2C8—liver—stomach cancer	0.000479	0.00282	CbGeAlD
Bortezomib—CYP2C9—endocrine gland—stomach cancer	0.000472	0.00278	CbGeAlD
Bortezomib—CYP1A2—liver—stomach cancer	0.000448	0.00264	CbGeAlD
Bortezomib—CYP1A1—liver—stomach cancer	0.000442	0.0026	CbGeAlD
Bortezomib—CYP3A4—digestive system—stomach cancer	0.000435	0.00256	CbGeAlD
Bortezomib—PTGS1—endocrine gland—stomach cancer	0.000431	0.00254	CbGeAlD
Bortezomib—CYP2D6—digestive system—stomach cancer	0.000428	0.00252	CbGeAlD
Bortezomib—CYP2C9—liver—stomach cancer	0.000425	0.0025	CbGeAlD
Bortezomib—CYP3A4—endocrine gland—stomach cancer	0.00036	0.00212	CbGeAlD
Bortezomib—Nateglinide—ALB—stomach cancer	0.000358	0.0741	CrCbGaD
Bortezomib—CYP2D6—endocrine gland—stomach cancer	0.000354	0.00208	CbGeAlD
Bortezomib—CYP1A1—lymph node—stomach cancer	0.000339	0.002	CbGeAlD
Bortezomib—CYP3A4—liver—stomach cancer	0.000324	0.00191	CbGeAlD
Bortezomib—CYP2D6—liver—stomach cancer	0.000319	0.00188	CbGeAlD
Bortezomib—PTGS1—lymph node—stomach cancer	0.000298	0.00175	CbGeAlD
Bortezomib—Musculoskeletal discomfort—Capecitabine—stomach cancer	7.76e-05	0.000187	CcSEcCtD
Bortezomib—Cardiac disorder—Epirubicin—stomach cancer	7.76e-05	0.000187	CcSEcCtD
Bortezomib—Flushing—Epirubicin—stomach cancer	7.76e-05	0.000187	CcSEcCtD
Bortezomib—Vomiting—Fluorouracil—stomach cancer	7.75e-05	0.000187	CcSEcCtD
Bortezomib—Dyspepsia—Docetaxel—stomach cancer	7.75e-05	0.000187	CcSEcCtD
Bortezomib—Haemorrhage—Doxorubicin—stomach cancer	7.73e-05	0.000186	CcSEcCtD
Bortezomib—Hepatitis—Doxorubicin—stomach cancer	7.73e-05	0.000186	CcSEcCtD
Bortezomib—Insomnia—Capecitabine—stomach cancer	7.71e-05	0.000186	CcSEcCtD
Bortezomib—Hypoaesthesia—Doxorubicin—stomach cancer	7.69e-05	0.000186	CcSEcCtD
Bortezomib—Rash—Fluorouracil—stomach cancer	7.69e-05	0.000185	CcSEcCtD
Bortezomib—Dermatitis—Fluorouracil—stomach cancer	7.68e-05	0.000185	CcSEcCtD
Bortezomib—Paraesthesia—Capecitabine—stomach cancer	7.65e-05	0.000185	CcSEcCtD
Bortezomib—Decreased appetite—Docetaxel—stomach cancer	7.65e-05	0.000185	CcSEcCtD
Bortezomib—Headache—Fluorouracil—stomach cancer	7.64e-05	0.000184	CcSEcCtD
Bortezomib—Urinary tract disorder—Doxorubicin—stomach cancer	7.64e-05	0.000184	CcSEcCtD
Bortezomib—Oedema peripheral—Doxorubicin—stomach cancer	7.62e-05	0.000184	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—stomach cancer	7.61e-05	0.000184	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Docetaxel—stomach cancer	7.6e-05	0.000183	CcSEcCtD
Bortezomib—Connective tissue disorder—Doxorubicin—stomach cancer	7.6e-05	0.000183	CcSEcCtD
Bortezomib—Dyspnoea—Capecitabine—stomach cancer	7.6e-05	0.000183	CcSEcCtD
Bortezomib—Fatigue—Docetaxel—stomach cancer	7.59e-05	0.000183	CcSEcCtD
Bortezomib—Angiopathy—Epirubicin—stomach cancer	7.58e-05	0.000183	CcSEcCtD
Bortezomib—Urethral disorder—Doxorubicin—stomach cancer	7.58e-05	0.000183	CcSEcCtD
Bortezomib—Nausea—Irinotecan—stomach cancer	7.56e-05	0.000182	CcSEcCtD
Bortezomib—Immune system disorder—Epirubicin—stomach cancer	7.55e-05	0.000182	CcSEcCtD
Bortezomib—Mediastinal disorder—Epirubicin—stomach cancer	7.53e-05	0.000182	CcSEcCtD
Bortezomib—Pain—Docetaxel—stomach cancer	7.53e-05	0.000182	CcSEcCtD
Bortezomib—Constipation—Docetaxel—stomach cancer	7.53e-05	0.000182	CcSEcCtD
Bortezomib—Back pain—Methotrexate—stomach cancer	7.52e-05	0.000181	CcSEcCtD
Bortezomib—Dyspepsia—Capecitabine—stomach cancer	7.5e-05	0.000181	CcSEcCtD
Bortezomib—Chills—Epirubicin—stomach cancer	7.5e-05	0.000181	CcSEcCtD
Bortezomib—Arrhythmia—Epirubicin—stomach cancer	7.47e-05	0.00018	CcSEcCtD
Bortezomib—Visual impairment—Doxorubicin—stomach cancer	7.45e-05	0.00018	CcSEcCtD
Bortezomib—Decreased appetite—Capecitabine—stomach cancer	7.41e-05	0.000179	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Capecitabine—stomach cancer	7.36e-05	0.000177	CcSEcCtD
Bortezomib—Fatigue—Capecitabine—stomach cancer	7.35e-05	0.000177	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—stomach cancer	7.33e-05	0.000177	CcSEcCtD
Bortezomib—Mental disorder—Epirubicin—stomach cancer	7.32e-05	0.000177	CcSEcCtD
Bortezomib—Erythema multiforme—Doxorubicin—stomach cancer	7.31e-05	0.000176	CcSEcCtD
Bortezomib—Constipation—Capecitabine—stomach cancer	7.29e-05	0.000176	CcSEcCtD
Bortezomib—Pain—Capecitabine—stomach cancer	7.29e-05	0.000176	CcSEcCtD
Bortezomib—Erythema—Epirubicin—stomach cancer	7.27e-05	0.000175	CcSEcCtD
Bortezomib—Malnutrition—Epirubicin—stomach cancer	7.27e-05	0.000175	CcSEcCtD
Bortezomib—Feeling abnormal—Docetaxel—stomach cancer	7.25e-05	0.000175	CcSEcCtD
Bortezomib—Nausea—Fluorouracil—stomach cancer	7.24e-05	0.000175	CcSEcCtD
Bortezomib—Eye disorder—Doxorubicin—stomach cancer	7.23e-05	0.000174	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—stomach cancer	7.21e-05	0.000174	CcSEcCtD
Bortezomib—Tinnitus—Doxorubicin—stomach cancer	7.21e-05	0.000174	CcSEcCtD
Bortezomib—Gastrointestinal pain—Docetaxel—stomach cancer	7.2e-05	0.000174	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—stomach cancer	7.18e-05	0.000173	CcSEcCtD
Bortezomib—Flushing—Doxorubicin—stomach cancer	7.18e-05	0.000173	CcSEcCtD
Bortezomib—Cardiac disorder—Doxorubicin—stomach cancer	7.18e-05	0.000173	CcSEcCtD
Bortezomib—Flatulence—Epirubicin—stomach cancer	7.17e-05	0.000173	CcSEcCtD
Bortezomib—Dysgeusia—Epirubicin—stomach cancer	7.12e-05	0.000172	CcSEcCtD
Bortezomib—Back pain—Epirubicin—stomach cancer	7.04e-05	0.00017	CcSEcCtD
Bortezomib—Feeling abnormal—Capecitabine—stomach cancer	7.02e-05	0.000169	CcSEcCtD
Bortezomib—Angiopathy—Doxorubicin—stomach cancer	7.02e-05	0.000169	CcSEcCtD
Bortezomib—Malaise—Methotrexate—stomach cancer	7.01e-05	0.000169	CcSEcCtD
Bortezomib—Muscle spasms—Epirubicin—stomach cancer	6.99e-05	0.000169	CcSEcCtD
Bortezomib—Immune system disorder—Doxorubicin—stomach cancer	6.98e-05	0.000168	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—stomach cancer	6.98e-05	0.000168	CcSEcCtD
Bortezomib—Gastrointestinal pain—Capecitabine—stomach cancer	6.97e-05	0.000168	CcSEcCtD
Bortezomib—Mediastinal disorder—Doxorubicin—stomach cancer	6.97e-05	0.000168	CcSEcCtD
Bortezomib—Body temperature increased—Docetaxel—stomach cancer	6.96e-05	0.000168	CcSEcCtD
Bortezomib—Abdominal pain—Docetaxel—stomach cancer	6.96e-05	0.000168	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—stomach cancer	6.96e-05	0.000168	CcSEcCtD
Bortezomib—Chills—Doxorubicin—stomach cancer	6.94e-05	0.000167	CcSEcCtD
Bortezomib—Arrhythmia—Doxorubicin—stomach cancer	6.91e-05	0.000167	CcSEcCtD
Bortezomib—Vision blurred—Epirubicin—stomach cancer	6.86e-05	0.000165	CcSEcCtD
Bortezomib—Cough—Methotrexate—stomach cancer	6.78e-05	0.000164	CcSEcCtD
Bortezomib—Mental disorder—Doxorubicin—stomach cancer	6.77e-05	0.000163	CcSEcCtD
Bortezomib—Urticaria—Capecitabine—stomach cancer	6.77e-05	0.000163	CcSEcCtD
Bortezomib—Ill-defined disorder—Epirubicin—stomach cancer	6.75e-05	0.000163	CcSEcCtD
Bortezomib—Body temperature increased—Capecitabine—stomach cancer	6.74e-05	0.000162	CcSEcCtD
Bortezomib—Abdominal pain—Capecitabine—stomach cancer	6.74e-05	0.000162	CcSEcCtD
Bortezomib—Convulsion—Methotrexate—stomach cancer	6.74e-05	0.000162	CcSEcCtD
Bortezomib—Malnutrition—Doxorubicin—stomach cancer	6.73e-05	0.000162	CcSEcCtD
Bortezomib—Erythema—Doxorubicin—stomach cancer	6.73e-05	0.000162	CcSEcCtD
Bortezomib—Anaemia—Epirubicin—stomach cancer	6.72e-05	0.000162	CcSEcCtD
Bortezomib—Agitation—Epirubicin—stomach cancer	6.69e-05	0.000161	CcSEcCtD
Bortezomib—Flatulence—Doxorubicin—stomach cancer	6.63e-05	0.00016	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—stomach cancer	6.62e-05	0.00016	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—stomach cancer	6.62e-05	0.00016	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—stomach cancer	6.62e-05	0.00016	CcSEcCtD
Bortezomib—Dysgeusia—Doxorubicin—stomach cancer	6.59e-05	0.000159	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	6.57e-05	0.000158	CcSEcCtD
Bortezomib—Malaise—Epirubicin—stomach cancer	6.56e-05	0.000158	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—stomach cancer	6.54e-05	0.000158	CcSEcCtD
Bortezomib—Vertigo—Epirubicin—stomach cancer	6.54e-05	0.000158	CcSEcCtD
Bortezomib—Syncope—Epirubicin—stomach cancer	6.52e-05	0.000157	CcSEcCtD
Bortezomib—Leukopenia—Epirubicin—stomach cancer	6.51e-05	0.000157	CcSEcCtD
Bortezomib—Back pain—Doxorubicin—stomach cancer	6.51e-05	0.000157	CcSEcCtD
Bortezomib—Hypersensitivity—Docetaxel—stomach cancer	6.49e-05	0.000156	CcSEcCtD
Bortezomib—Muscle spasms—Doxorubicin—stomach cancer	6.47e-05	0.000156	CcSEcCtD
Bortezomib—Palpitations—Epirubicin—stomach cancer	6.43e-05	0.000155	CcSEcCtD
Bortezomib—Confusional state—Methotrexate—stomach cancer	6.4e-05	0.000154	CcSEcCtD
Bortezomib—Loss of consciousness—Epirubicin—stomach cancer	6.39e-05	0.000154	CcSEcCtD
Bortezomib—Cough—Epirubicin—stomach cancer	6.35e-05	0.000153	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—stomach cancer	6.34e-05	0.000153	CcSEcCtD
Bortezomib—Vision blurred—Doxorubicin—stomach cancer	6.34e-05	0.000153	CcSEcCtD
Bortezomib—Asthenia—Docetaxel—stomach cancer	6.32e-05	0.000152	CcSEcCtD
Bortezomib—Convulsion—Epirubicin—stomach cancer	6.3e-05	0.000152	CcSEcCtD
Bortezomib—Infection—Methotrexate—stomach cancer	6.3e-05	0.000152	CcSEcCtD
Bortezomib—Hypertension—Epirubicin—stomach cancer	6.28e-05	0.000151	CcSEcCtD
Bortezomib—Hypersensitivity—Capecitabine—stomach cancer	6.28e-05	0.000151	CcSEcCtD
Bortezomib—Ill-defined disorder—Doxorubicin—stomach cancer	6.25e-05	0.000151	CcSEcCtD
Bortezomib—Pruritus—Docetaxel—stomach cancer	6.23e-05	0.00015	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—stomach cancer	6.22e-05	0.00015	CcSEcCtD
Bortezomib—Anaemia—Doxorubicin—stomach cancer	6.22e-05	0.00015	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—stomach cancer	6.21e-05	0.00015	CcSEcCtD
Bortezomib—Chest pain—Epirubicin—stomach cancer	6.19e-05	0.000149	CcSEcCtD
Bortezomib—Arthralgia—Epirubicin—stomach cancer	6.19e-05	0.000149	CcSEcCtD
Bortezomib—Myalgia—Epirubicin—stomach cancer	6.19e-05	0.000149	CcSEcCtD
Bortezomib—Agitation—Doxorubicin—stomach cancer	6.19e-05	0.000149	CcSEcCtD
Bortezomib—Anxiety—Epirubicin—stomach cancer	6.17e-05	0.000149	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—stomach cancer	6.16e-05	0.000149	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	6.15e-05	0.000148	CcSEcCtD
Bortezomib—Hyperhidrosis—Methotrexate—stomach cancer	6.13e-05	0.000148	CcSEcCtD
Bortezomib—Discomfort—Epirubicin—stomach cancer	6.12e-05	0.000148	CcSEcCtD
Bortezomib—Asthenia—Capecitabine—stomach cancer	6.11e-05	0.000147	CcSEcCtD
Bortezomib—Malaise—Doxorubicin—stomach cancer	6.07e-05	0.000146	CcSEcCtD
Bortezomib—Vertigo—Doxorubicin—stomach cancer	6.05e-05	0.000146	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—stomach cancer	6.05e-05	0.000146	CcSEcCtD
Bortezomib—Syncope—Doxorubicin—stomach cancer	6.04e-05	0.000146	CcSEcCtD
Bortezomib—Pruritus—Capecitabine—stomach cancer	6.03e-05	0.000145	CcSEcCtD
Bortezomib—Leukopenia—Doxorubicin—stomach cancer	6.03e-05	0.000145	CcSEcCtD
Bortezomib—Diarrhoea—Docetaxel—stomach cancer	6.02e-05	0.000145	CcSEcCtD
Bortezomib—Confusional state—Epirubicin—stomach cancer	5.99e-05	0.000144	CcSEcCtD
Bortezomib—Palpitations—Doxorubicin—stomach cancer	5.95e-05	0.000143	CcSEcCtD
Bortezomib—Anaphylactic shock—Epirubicin—stomach cancer	5.94e-05	0.000143	CcSEcCtD
Bortezomib—Oedema—Epirubicin—stomach cancer	5.94e-05	0.000143	CcSEcCtD
Bortezomib—Hypotension—Methotrexate—stomach cancer	5.93e-05	0.000143	CcSEcCtD
Bortezomib—Loss of consciousness—Doxorubicin—stomach cancer	5.92e-05	0.000143	CcSEcCtD
Bortezomib—Infection—Epirubicin—stomach cancer	5.9e-05	0.000142	CcSEcCtD
Bortezomib—Cough—Doxorubicin—stomach cancer	5.87e-05	0.000142	CcSEcCtD
Bortezomib—Shock—Epirubicin—stomach cancer	5.84e-05	0.000141	CcSEcCtD
Bortezomib—Convulsion—Doxorubicin—stomach cancer	5.83e-05	0.000141	CcSEcCtD
Bortezomib—Diarrhoea—Capecitabine—stomach cancer	5.83e-05	0.000141	CcSEcCtD
Bortezomib—Nervous system disorder—Epirubicin—stomach cancer	5.82e-05	0.00014	CcSEcCtD
Bortezomib—Dizziness—Docetaxel—stomach cancer	5.82e-05	0.00014	CcSEcCtD
Bortezomib—Thrombocytopenia—Epirubicin—stomach cancer	5.81e-05	0.00014	CcSEcCtD
Bortezomib—Hypertension—Doxorubicin—stomach cancer	5.81e-05	0.00014	CcSEcCtD
Bortezomib—Tachycardia—Epirubicin—stomach cancer	5.79e-05	0.00014	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methotrexate—stomach cancer	5.78e-05	0.000139	CcSEcCtD
Bortezomib—Skin disorder—Epirubicin—stomach cancer	5.77e-05	0.000139	CcSEcCtD
Bortezomib—Hyperhidrosis—Epirubicin—stomach cancer	5.74e-05	0.000138	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—stomach cancer	5.74e-05	0.000138	CcSEcCtD
Bortezomib—Myalgia—Doxorubicin—stomach cancer	5.73e-05	0.000138	CcSEcCtD
Bortezomib—Chest pain—Doxorubicin—stomach cancer	5.73e-05	0.000138	CcSEcCtD
Bortezomib—Arthralgia—Doxorubicin—stomach cancer	5.73e-05	0.000138	CcSEcCtD
Bortezomib—Anxiety—Doxorubicin—stomach cancer	5.71e-05	0.000138	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—stomach cancer	5.7e-05	0.000137	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	5.69e-05	0.000137	CcSEcCtD
Bortezomib—Discomfort—Doxorubicin—stomach cancer	5.66e-05	0.000137	CcSEcCtD
Bortezomib—Anorexia—Epirubicin—stomach cancer	5.66e-05	0.000136	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—stomach cancer	5.66e-05	0.000136	CcSEcCtD
Bortezomib—Dizziness—Capecitabine—stomach cancer	5.64e-05	0.000136	CcSEcCtD
Bortezomib—Vomiting—Docetaxel—stomach cancer	5.6e-05	0.000135	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—stomach cancer	5.58e-05	0.000135	CcSEcCtD
Bortezomib—Rash—Docetaxel—stomach cancer	5.55e-05	0.000134	CcSEcCtD
Bortezomib—Hypotension—Epirubicin—stomach cancer	5.55e-05	0.000134	CcSEcCtD
Bortezomib—Dermatitis—Docetaxel—stomach cancer	5.54e-05	0.000134	CcSEcCtD
Bortezomib—Confusional state—Doxorubicin—stomach cancer	5.54e-05	0.000134	CcSEcCtD
Bortezomib—Decreased appetite—Methotrexate—stomach cancer	5.51e-05	0.000133	CcSEcCtD
Bortezomib—Headache—Docetaxel—stomach cancer	5.51e-05	0.000133	CcSEcCtD
Bortezomib—Anaphylactic shock—Doxorubicin—stomach cancer	5.49e-05	0.000132	CcSEcCtD
Bortezomib—Oedema—Doxorubicin—stomach cancer	5.49e-05	0.000132	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—stomach cancer	5.48e-05	0.000132	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—stomach cancer	5.47e-05	0.000132	CcSEcCtD
Bortezomib—Infection—Doxorubicin—stomach cancer	5.46e-05	0.000132	CcSEcCtD
Bortezomib—Pain—Methotrexate—stomach cancer	5.43e-05	0.000131	CcSEcCtD
Bortezomib—Vomiting—Capecitabine—stomach cancer	5.42e-05	0.000131	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Epirubicin—stomach cancer	5.41e-05	0.00013	CcSEcCtD
Bortezomib—Shock—Doxorubicin—stomach cancer	5.4e-05	0.00013	CcSEcCtD
Bortezomib—Nervous system disorder—Doxorubicin—stomach cancer	5.39e-05	0.00013	CcSEcCtD
Bortezomib—Thrombocytopenia—Doxorubicin—stomach cancer	5.38e-05	0.00013	CcSEcCtD
Bortezomib—Rash—Capecitabine—stomach cancer	5.37e-05	0.00013	CcSEcCtD
Bortezomib—Insomnia—Epirubicin—stomach cancer	5.37e-05	0.000129	CcSEcCtD
Bortezomib—Dermatitis—Capecitabine—stomach cancer	5.37e-05	0.000129	CcSEcCtD
Bortezomib—Tachycardia—Doxorubicin—stomach cancer	5.36e-05	0.000129	CcSEcCtD
Bortezomib—Headache—Capecitabine—stomach cancer	5.34e-05	0.000129	CcSEcCtD
Bortezomib—Skin disorder—Doxorubicin—stomach cancer	5.34e-05	0.000129	CcSEcCtD
Bortezomib—Paraesthesia—Epirubicin—stomach cancer	5.33e-05	0.000129	CcSEcCtD
Bortezomib—Hyperhidrosis—Doxorubicin—stomach cancer	5.31e-05	0.000128	CcSEcCtD
Bortezomib—Dyspnoea—Epirubicin—stomach cancer	5.29e-05	0.000128	CcSEcCtD
Bortezomib—Anorexia—Doxorubicin—stomach cancer	5.24e-05	0.000126	CcSEcCtD
Bortezomib—Nausea—Docetaxel—stomach cancer	5.23e-05	0.000126	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—stomach cancer	5.23e-05	0.000126	CcSEcCtD
Bortezomib—Dyspepsia—Epirubicin—stomach cancer	5.23e-05	0.000126	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—stomach cancer	5.19e-05	0.000125	CcSEcCtD
Bortezomib—Decreased appetite—Epirubicin—stomach cancer	5.16e-05	0.000124	CcSEcCtD
Bortezomib—Hypotension—Doxorubicin—stomach cancer	5.13e-05	0.000124	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Epirubicin—stomach cancer	5.13e-05	0.000124	CcSEcCtD
Bortezomib—Fatigue—Epirubicin—stomach cancer	5.12e-05	0.000123	CcSEcCtD
Bortezomib—Pain—Epirubicin—stomach cancer	5.08e-05	0.000122	CcSEcCtD
Bortezomib—Constipation—Epirubicin—stomach cancer	5.08e-05	0.000122	CcSEcCtD
Bortezomib—Nausea—Capecitabine—stomach cancer	5.06e-05	0.000122	CcSEcCtD
Bortezomib—Urticaria—Methotrexate—stomach cancer	5.04e-05	0.000122	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—stomach cancer	5.02e-05	0.000121	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—stomach cancer	5.02e-05	0.000121	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Doxorubicin—stomach cancer	5e-05	0.000121	CcSEcCtD
Bortezomib—Insomnia—Doxorubicin—stomach cancer	4.97e-05	0.00012	CcSEcCtD
Bortezomib—Paraesthesia—Doxorubicin—stomach cancer	4.93e-05	0.000119	CcSEcCtD
Bortezomib—Dyspnoea—Doxorubicin—stomach cancer	4.9e-05	0.000118	CcSEcCtD
Bortezomib—Feeling abnormal—Epirubicin—stomach cancer	4.89e-05	0.000118	CcSEcCtD
Bortezomib—Gastrointestinal pain—Epirubicin—stomach cancer	4.85e-05	0.000117	CcSEcCtD
Bortezomib—Dyspepsia—Doxorubicin—stomach cancer	4.84e-05	0.000117	CcSEcCtD
Bortezomib—Decreased appetite—Doxorubicin—stomach cancer	4.78e-05	0.000115	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Doxorubicin—stomach cancer	4.74e-05	0.000114	CcSEcCtD
Bortezomib—Fatigue—Doxorubicin—stomach cancer	4.74e-05	0.000114	CcSEcCtD
Bortezomib—Urticaria—Epirubicin—stomach cancer	4.72e-05	0.000114	CcSEcCtD
Bortezomib—Constipation—Doxorubicin—stomach cancer	4.7e-05	0.000113	CcSEcCtD
Bortezomib—Pain—Doxorubicin—stomach cancer	4.7e-05	0.000113	CcSEcCtD
Bortezomib—Abdominal pain—Epirubicin—stomach cancer	4.69e-05	0.000113	CcSEcCtD
Bortezomib—Body temperature increased—Epirubicin—stomach cancer	4.69e-05	0.000113	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—stomach cancer	4.67e-05	0.000113	CcSEcCtD
Bortezomib—Asthenia—Methotrexate—stomach cancer	4.55e-05	0.00011	CcSEcCtD
Bortezomib—Feeling abnormal—Doxorubicin—stomach cancer	4.53e-05	0.000109	CcSEcCtD
Bortezomib—Gastrointestinal pain—Doxorubicin—stomach cancer	4.49e-05	0.000108	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—stomach cancer	4.49e-05	0.000108	CcSEcCtD
Bortezomib—Hypersensitivity—Epirubicin—stomach cancer	4.37e-05	0.000105	CcSEcCtD
Bortezomib—Urticaria—Doxorubicin—stomach cancer	4.36e-05	0.000105	CcSEcCtD
Bortezomib—Abdominal pain—Doxorubicin—stomach cancer	4.34e-05	0.000105	CcSEcCtD
Bortezomib—Body temperature increased—Doxorubicin—stomach cancer	4.34e-05	0.000105	CcSEcCtD
Bortezomib—Diarrhoea—Methotrexate—stomach cancer	4.34e-05	0.000105	CcSEcCtD
Bortezomib—Asthenia—Epirubicin—stomach cancer	4.26e-05	0.000103	CcSEcCtD
Bortezomib—Pruritus—Epirubicin—stomach cancer	4.2e-05	0.000101	CcSEcCtD
Bortezomib—Dizziness—Methotrexate—stomach cancer	4.2e-05	0.000101	CcSEcCtD
Bortezomib—Diarrhoea—Epirubicin—stomach cancer	4.06e-05	9.8e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Doxorubicin—stomach cancer	4.05e-05	9.76e-05	CcSEcCtD
Bortezomib—Vomiting—Methotrexate—stomach cancer	4.03e-05	9.73e-05	CcSEcCtD
Bortezomib—Rash—Methotrexate—stomach cancer	4e-05	9.65e-05	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—stomach cancer	4e-05	9.64e-05	CcSEcCtD
Bortezomib—Headache—Methotrexate—stomach cancer	3.97e-05	9.58e-05	CcSEcCtD
Bortezomib—Asthenia—Doxorubicin—stomach cancer	3.94e-05	9.5e-05	CcSEcCtD
Bortezomib—Dizziness—Epirubicin—stomach cancer	3.93e-05	9.47e-05	CcSEcCtD
Bortezomib—Pruritus—Doxorubicin—stomach cancer	3.89e-05	9.37e-05	CcSEcCtD
Bortezomib—Vomiting—Epirubicin—stomach cancer	3.77e-05	9.1e-05	CcSEcCtD
Bortezomib—Nausea—Methotrexate—stomach cancer	3.77e-05	9.09e-05	CcSEcCtD
Bortezomib—Diarrhoea—Doxorubicin—stomach cancer	3.76e-05	9.06e-05	CcSEcCtD
Bortezomib—Rash—Epirubicin—stomach cancer	3.74e-05	9.03e-05	CcSEcCtD
Bortezomib—Dermatitis—Epirubicin—stomach cancer	3.74e-05	9.02e-05	CcSEcCtD
Bortezomib—Headache—Epirubicin—stomach cancer	3.72e-05	8.97e-05	CcSEcCtD
Bortezomib—Dizziness—Doxorubicin—stomach cancer	3.63e-05	8.76e-05	CcSEcCtD
Bortezomib—Nausea—Epirubicin—stomach cancer	3.53e-05	8.5e-05	CcSEcCtD
Bortezomib—Vomiting—Doxorubicin—stomach cancer	3.49e-05	8.42e-05	CcSEcCtD
Bortezomib—Rash—Doxorubicin—stomach cancer	3.46e-05	8.35e-05	CcSEcCtD
Bortezomib—Dermatitis—Doxorubicin—stomach cancer	3.46e-05	8.34e-05	CcSEcCtD
Bortezomib—Headache—Doxorubicin—stomach cancer	3.44e-05	8.3e-05	CcSEcCtD
Bortezomib—Nausea—Doxorubicin—stomach cancer	3.26e-05	7.87e-05	CcSEcCtD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—stomach cancer	6.5e-06	1.93e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—stomach cancer	6.49e-06	1.93e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	6.46e-06	1.92e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP2A6—stomach cancer	6.45e-06	1.92e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CAV1—stomach cancer	6.44e-06	1.92e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCND1—stomach cancer	6.44e-06	1.92e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCND1—stomach cancer	6.44e-06	1.92e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCND1—stomach cancer	6.44e-06	1.92e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—APOA1—stomach cancer	6.43e-06	1.91e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—JUN—stomach cancer	6.43e-06	1.91e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—JUN—stomach cancer	6.43e-06	1.91e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—JUN—stomach cancer	6.43e-06	1.91e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALOX5—stomach cancer	6.41e-06	1.91e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCND1—stomach cancer	6.35e-06	1.89e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—JUN—stomach cancer	6.34e-06	1.89e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKR1C3—stomach cancer	6.33e-06	1.88e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—DPYD—stomach cancer	6.3e-06	1.88e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KRAS—stomach cancer	6.3e-06	1.87e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HRAS—stomach cancer	6.28e-06	1.87e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HRAS—stomach cancer	6.28e-06	1.87e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HRAS—stomach cancer	6.28e-06	1.87e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKR1C3—stomach cancer	6.27e-06	1.87e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KRAS—stomach cancer	6.27e-06	1.87e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PIK3CA—stomach cancer	6.26e-06	1.86e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PIK3CA—stomach cancer	6.26e-06	1.86e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PIK3CA—stomach cancer	6.26e-06	1.86e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MMP9—stomach cancer	6.25e-06	1.86e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MMP9—stomach cancer	6.25e-06	1.86e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MMP9—stomach cancer	6.25e-06	1.86e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KRAS—stomach cancer	6.24e-06	1.86e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CDKN1A—stomach cancer	6.23e-06	1.85e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CDKN1A—stomach cancer	6.23e-06	1.85e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CDKN1A—stomach cancer	6.23e-06	1.85e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HRAS—stomach cancer	6.19e-06	1.84e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPP2R1A—stomach cancer	6.18e-06	1.84e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PIK3CA—stomach cancer	6.17e-06	1.84e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ENO1—stomach cancer	6.17e-06	1.84e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MMP9—stomach cancer	6.16e-06	1.83e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	6.16e-06	1.83e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CDKN1A—stomach cancer	6.14e-06	1.83e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TYMP—stomach cancer	6.14e-06	1.83e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—FADS1—stomach cancer	6.14e-06	1.83e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ENO1—stomach cancer	6.11e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK8—stomach cancer	6.08e-06	1.81e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK8—stomach cancer	6.08e-06	1.81e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK8—stomach cancer	6.08e-06	1.81e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTP1—stomach cancer	6.06e-06	1.8e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—stomach cancer	6.01e-06	1.79e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL6—stomach cancer	6.01e-06	1.79e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL6—stomach cancer	6.01e-06	1.79e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL6—stomach cancer	6.01e-06	1.79e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK8—stomach cancer	6e-06	1.78e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—HMOX1—stomach cancer	5.98e-06	1.78e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CD44—stomach cancer	5.95e-06	1.77e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL6—stomach cancer	5.92e-06	1.76e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—stomach cancer	5.79e-06	1.72e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—stomach cancer	5.79e-06	1.72e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—stomach cancer	5.79e-06	1.72e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—PIK3CA—stomach cancer	5.79e-06	1.72e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	5.77e-06	1.72e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PIK3CA—stomach cancer	5.76e-06	1.71e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SREBF2—stomach cancer	5.75e-06	1.71e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PIK3CA—stomach cancer	5.73e-06	1.71e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—stomach cancer	5.71e-06	1.7e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—stomach cancer	5.71e-06	1.7e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—RORA—stomach cancer	5.68e-06	1.69e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PPARG—stomach cancer	5.67e-06	1.69e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPP2R1A—stomach cancer	5.66e-06	1.69e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—TYMS—stomach cancer	5.63e-06	1.68e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—stomach cancer	5.61e-06	1.67e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—stomach cancer	5.61e-06	1.67e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—stomach cancer	5.61e-06	1.67e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—stomach cancer	5.6e-06	1.67e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTT1—stomach cancer	5.58e-06	1.66e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—stomach cancer	5.57e-06	1.66e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTM1—stomach cancer	5.57e-06	1.66e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—STAT3—stomach cancer	5.56e-06	1.65e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—STAT3—stomach cancer	5.56e-06	1.65e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—STAT3—stomach cancer	5.56e-06	1.65e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTP1—stomach cancer	5.56e-06	1.65e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—stomach cancer	5.55e-06	1.65e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—stomach cancer	5.55e-06	1.65e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—stomach cancer	5.55e-06	1.65e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—stomach cancer	5.54e-06	1.65e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—stomach cancer	5.54e-06	1.65e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP2A6—stomach cancer	5.51e-06	1.64e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—STAT3—stomach cancer	5.48e-06	1.63e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—HMOX1—stomach cancer	5.48e-06	1.63e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CD44—stomach cancer	5.47e-06	1.63e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—stomach cancer	5.47e-06	1.63e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CD44—stomach cancer	5.42e-06	1.61e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKR1C3—stomach cancer	5.36e-06	1.6e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—stomach cancer	5.35e-06	1.59e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—stomach cancer	5.33e-06	1.59e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALDOB—stomach cancer	5.32e-06	1.58e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK3—stomach cancer	5.31e-06	1.58e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK3—stomach cancer	5.31e-06	1.58e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK3—stomach cancer	5.31e-06	1.58e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—stomach cancer	5.3e-06	1.58e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	5.26e-06	1.57e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PIK3CA—stomach cancer	5.24e-06	1.56e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PIK3CA—stomach cancer	5.24e-06	1.56e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PIK3CA—stomach cancer	5.24e-06	1.56e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ERCC2—stomach cancer	5.24e-06	1.56e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK3—stomach cancer	5.24e-06	1.56e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ENO1—stomach cancer	5.22e-06	1.55e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PIK3CA—stomach cancer	5.17e-06	1.54e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—stomach cancer	5.17e-06	1.54e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—stomach cancer	5.17e-06	1.54e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—stomach cancer	5.17e-06	1.54e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—TYMS—stomach cancer	5.17e-06	1.54e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—stomach cancer	5.14e-06	1.53e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—stomach cancer	5.12e-06	1.52e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTM1—stomach cancer	5.11e-06	1.52e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—stomach cancer	5.1e-06	1.52e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—stomach cancer	5.09e-06	1.52e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—stomach cancer	5.09e-06	1.52e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—stomach cancer	5.08e-06	1.51e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPP2R1A—stomach cancer	5.06e-06	1.5e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK1—stomach cancer	5.05e-06	1.5e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK1—stomach cancer	5.05e-06	1.5e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK1—stomach cancer	5.05e-06	1.5e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—stomach cancer	5.05e-06	1.5e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—stomach cancer	5.05e-06	1.5e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—stomach cancer	5.05e-06	1.5e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK1—stomach cancer	4.98e-06	1.48e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—stomach cancer	4.98e-06	1.48e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTP1—stomach cancer	4.96e-06	1.48e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALOX5—stomach cancer	4.95e-06	1.47e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MTHFR—stomach cancer	4.92e-06	1.46e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—HMOX1—stomach cancer	4.89e-06	1.46e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—NOS3—stomach cancer	4.87e-06	1.45e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—DPYD—stomach cancer	4.87e-06	1.45e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ERCC2—stomach cancer	4.8e-06	1.43e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—stomach cancer	4.77e-06	1.42e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—stomach cancer	4.77e-06	1.42e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—stomach cancer	4.77e-06	1.42e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—stomach cancer	4.71e-06	1.4e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPP2R1A—stomach cancer	4.65e-06	1.38e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CD44—stomach cancer	4.63e-06	1.38e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—TYMS—stomach cancer	4.61e-06	1.37e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPP2R1A—stomach cancer	4.61e-06	1.37e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTP1—stomach cancer	4.56e-06	1.36e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTM1—stomach cancer	4.56e-06	1.36e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CAV1—stomach cancer	4.54e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOA1—stomach cancer	4.53e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTP1—stomach cancer	4.52e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MTHFR—stomach cancer	4.51e-06	1.34e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HMOX1—stomach cancer	4.5e-06	1.34e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	4.5e-06	1.34e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HMOX1—stomach cancer	4.46e-06	1.33e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—stomach cancer	4.46e-06	1.33e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PIK3CA—stomach cancer	4.39e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PIK3CA—stomach cancer	4.39e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PIK3CA—stomach cancer	4.39e-06	1.31e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	4.34e-06	1.29e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PIK3CA—stomach cancer	4.32e-06	1.29e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTT1—stomach cancer	4.3e-06	1.28e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ERCC2—stomach cancer	4.29e-06	1.28e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP2A6—stomach cancer	4.25e-06	1.27e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—stomach cancer	4.24e-06	1.26e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—stomach cancer	4.24e-06	1.26e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—stomach cancer	4.24e-06	1.26e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—TYMS—stomach cancer	4.24e-06	1.26e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—TYMS—stomach cancer	4.2e-06	1.25e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTM1—stomach cancer	4.19e-06	1.25e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—stomach cancer	4.18e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CAV1—stomach cancer	4.16e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTM1—stomach cancer	4.16e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOA1—stomach cancer	4.15e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKR1C3—stomach cancer	4.14e-06	1.23e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—stomach cancer	4.06e-06	1.21e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—stomach cancer	4.06e-06	1.21e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—stomach cancer	4.06e-06	1.21e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ENO1—stomach cancer	4.03e-06	1.2e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MTHFR—stomach cancer	4.03e-06	1.2e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—stomach cancer	4e-06	1.19e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARG—stomach cancer	3.99e-06	1.19e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	3.98e-06	1.18e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ERCC2—stomach cancer	3.94e-06	1.17e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPP2R1A—stomach cancer	3.94e-06	1.17e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ERCC2—stomach cancer	3.91e-06	1.16e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—stomach cancer	3.88e-06	1.16e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—stomach cancer	3.88e-06	1.16e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—stomach cancer	3.88e-06	1.16e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTP1—stomach cancer	3.86e-06	1.15e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—stomach cancer	3.83e-06	1.14e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HMOX1—stomach cancer	3.81e-06	1.13e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CAV1—stomach cancer	3.72e-06	1.11e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOA1—stomach cancer	3.71e-06	1.1e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MTHFR—stomach cancer	3.7e-06	1.1e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MTHFR—stomach cancer	3.67e-06	1.09e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARG—stomach cancer	3.66e-06	1.09e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TYMS—stomach cancer	3.59e-06	1.07e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—stomach cancer	3.59e-06	1.07e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CD44—stomach cancer	3.58e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTM1—stomach cancer	3.55e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	3.55e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NOS3—stomach cancer	3.43e-06	1.02e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CAV1—stomach cancer	3.42e-06	1.02e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOA1—stomach cancer	3.41e-06	1.01e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CAV1—stomach cancer	3.39e-06	1.01e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOA1—stomach cancer	3.38e-06	1.01e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ERCC2—stomach cancer	3.34e-06	9.94e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—stomach cancer	3.29e-06	9.79e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARG—stomach cancer	3.27e-06	9.72e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	3.24e-06	9.63e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NOS3—stomach cancer	3.15e-06	9.37e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—stomach cancer	3.14e-06	9.34e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MTHFR—stomach cancer	3.14e-06	9.34e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPP2R1A—stomach cancer	3.04e-06	9.05e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARG—stomach cancer	3e-06	8.94e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTP1—stomach cancer	2.98e-06	8.88e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARG—stomach cancer	2.98e-06	8.86e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HMOX1—stomach cancer	2.94e-06	8.75e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—stomach cancer	2.94e-06	8.74e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CAV1—stomach cancer	2.89e-06	8.62e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOA1—stomach cancer	2.89e-06	8.6e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—stomach cancer	2.88e-06	8.57e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NOS3—stomach cancer	2.81e-06	8.36e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TYMS—stomach cancer	2.77e-06	8.25e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	2.77e-06	8.23e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CA—stomach cancer	2.74e-06	8.16e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTM1—stomach cancer	2.74e-06	8.16e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—stomach cancer	2.7e-06	8.04e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—stomach cancer	2.68e-06	7.97e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NOS3—stomach cancer	2.58e-06	7.69e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ERCC2—stomach cancer	2.58e-06	7.67e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—stomach cancer	2.57e-06	7.65e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NOS3—stomach cancer	2.56e-06	7.62e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARG—stomach cancer	2.54e-06	7.57e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTHFR—stomach cancer	2.42e-06	7.21e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—stomach cancer	2.36e-06	7.03e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—stomach cancer	2.34e-06	6.97e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—stomach cancer	2.29e-06	6.81e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CAV1—stomach cancer	2.23e-06	6.65e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOA1—stomach cancer	2.23e-06	6.63e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NOS3—stomach cancer	2.19e-06	6.51e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—stomach cancer	2e-06	5.96e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARG—stomach cancer	1.96e-06	5.85e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CA—stomach cancer	1.93e-06	5.75e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CA—stomach cancer	1.77e-06	5.27e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—stomach cancer	1.77e-06	5.26e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NOS3—stomach cancer	1.69e-06	5.03e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CA—stomach cancer	1.58e-06	4.7e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—stomach cancer	1.55e-06	4.6e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CA—stomach cancer	1.45e-06	4.33e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CA—stomach cancer	1.44e-06	4.29e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CA—stomach cancer	1.23e-06	3.67e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CA—stomach cancer	9.51e-07	2.83e-06	CbGpPWpGaD
